Skip to Content

Adjuvant Pembrolizumab Continue to Demonstrate Significant Improvements for Patients with Stage IIB/IIC Melanoma

For patients with stage IIB/IIC melanoma, adjuvant pembrolizumab provides a 41% reduction in the risk of distant metastasis or death and a 38% reduction in the risk of recurrence or death, according to an update from the KEYNOTE-716 trial presented at ASCO23.

Get access

If you are a doctor or other health professional, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top